Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free HRMY Stock Alerts

Harmony Biosciences (HRMY) Financials

Harmony Biosciences logo
$29.98 -0.78 (-2.53%)
As of 02:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Harmony Biosciences

Annual Income Statements for Harmony Biosciences

This table shows Harmony Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -187 -64 35 181 129 146 159
Consolidated Net Income / (Loss)		 -152 -37 35 181 129 145 159
Net Income / (Loss) Continuing Operations		 -152 -37 35 181 129 145 159
Total Pre-Tax Income 		-152 -37 37 105 173 192 215
Total Operating Income		 -146 17 88 120 192 191 208
Total Gross Profit		 4.42 132 250 354 461 558 670
Total Revenue		 6.00 160 305 438 582 715 868
Operating Revenue		 6.00 160 305 438 582 715 868
Total Cost of Revenue		 1.58 28 56 83 121 157 198
Operating Cost of Revenue		 1.58 28 56 83 121 157 198
Total Operating Expenses		 150 115 162 234 269 367 462
Selling, General & Admin Expense		 36 40 64 84 95 110 153
Marketing Expense		 44 56 68 79 97 111 120
Research & Development Expense		 70 19 30 71 76 146 190
Total Other Income / (Expense), net		 -6.07 -54 -50 -16 -19 0.98 6.60
Interest Expense		 0.00 23 50 19 34 17 15
Interest & Investment Income		 -6.07 -28 0.22 3.13 15 19 22
Other Income / (Expense), net		 0.00 -3.07 0.02 0.17 0.16 -0.07 -0.68
Income Tax Expense		 0.00 0.00 2.83 -77 45 46 56
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - 0.00 0.15 -0.15 -0.06 -0.28
Basic Earnings per Share		 ($24.07) ($2.48) $0.60 $3.07 $2.17 $2.56 $2.76
Weighted Average Basic Shares Outstanding		 7.78M 25.77M 57.53M 59.17M 59.47M 56.89M 57.49M
Diluted Earnings per Share		 ($24.07) ($2.48) $0.58 $2.97 $2.13 $2.51 $2.71
Weighted Average Diluted Shares Outstanding		 7.78M 25.77M 59.21M 61.10M 60.37M 57.87M 58.54M
Weighted Average Basic & Diluted Shares Outstanding		 - 56.89M 58.87M 59.62M 56.77M 57.35M 57.84M

Quarterly Income Statements for Harmony Biosciences

This table shows Harmony Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 38 27 38 12 47 49 46 40 51 22 32
Consolidated Net Income / (Loss)		 38 27 38 12 46 49 46 40 51 22 32
Net Income / (Loss) Continuing Operations		 38 27 38 12 46 49 46 40 51 22 32
Total Pre-Tax Income 		52 40 52 22 62 56 57 50 67 41 40
Total Operating Income		 65 40 52 21 62 56 56 48 65 39 37
Total Gross Profit		 128 125 127 141 143 147 153 162 180 175 171
Total Revenue		 160 168 155 173 186 201 185 200 239 244 215
Operating Revenue		 160 168 155 173 186 201 185 200 239 244 215
Total Cost of Revenue		 32 43 27 32 43 54 32 38 60 69 45
Operating Cost of Revenue		 32 43 27 32 43 54 32 38 60 69 45
Total Operating Expenses		 63 85 75 119 82 91 96 114 114 137 134
Selling, General & Admin Expense		 23 28 26 27 29 29 31 34 30 58 33
Marketing Expense		 23 27 27 29 28 28 31 30 30 29 32
Research & Development Expense		 17 30 22 64 25 35 35 50 55 50 69
Total Other Income / (Expense), net		 -13 -0.67 -0.25 0.34 0.46 0.43 0.93 1.46 2.00 2.20 2.40
Interest Expense		 17 4.80 4.54 4.40 4.35 4.21 3.84 3.65 3.62 3.55 3.23
Interest & Investment Income		 4.11 4.10 4.43 4.71 4.93 4.48 5.04 5.30 5.73 5.85 5.76
Other Income / (Expense), net		 -0.01 - -0.14 0.04 -0.12 0.16 -0.28 -0.19 -0.11 -0.11 -0.13
Income Tax Expense		 13 13 13 10 16 6.68 12 9.86 17 18 7.20
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -0.01 -0.52 0.17 0.06 -0.73 0.43 -0.18 0.01 -0.12 0.01 0.76
Basic Earnings per Share		 $0.64 $0.47 $0.68 $0.20 $0.81 $0.87 $0.79 $0.69 $0.88 $0.40 $0.56
Weighted Average Basic Shares Outstanding		 59.86M 59.47M 56.77M 56.80M 56.87M 56.89M 57.31M 57.47M 57.55M 57.49M 57.82M
Diluted Earnings per Share		 $0.63 $0.46 $0.67 $0.20 $0.79 $0.85 $0.78 $0.68 $0.87 $0.38 $0.55
Weighted Average Diluted Shares Outstanding		 60.68M 60.37M 57.60M 57.54M 58.10M 57.87M 58.52M 58.43M 58.72M 58.54M 58.78M
Weighted Average Basic & Diluted Shares Outstanding		 58.57M 56.77M 56.79M 56.83M 57.03M 57.35M 57.42M 57.53M 57.60M 57.84M 57.89M

Annual Cash Flow Statements for Harmony Biosciences

This table details how cash moves in and out of Harmony Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -59 204 5.68 9.48 67 141 300
Net Cash From Operating Activities		 -75 -2.99 99 144 219 220 348
Net Cash From Continuing Operating Activities		 -75 -2.99 99 144 219 220 347
Net Income / (Loss) Continuing Operations		 -152 -37 35 181 129 145 159
Consolidated Net Income / (Loss)		 -152 -37 35 181 129 145 159
Amortization Expense		 3.41 12 21 24 23 22 23
Non-Cash Adjustments To Reconcile Net Income		 64 33 42 28 45 88 81
Changes in Operating Assets and Liabilities, net		 8.29 -12 0.63 -90 22 -37 85
Net Cash From Investing Activities		 -127 -2.00 -100 -142 -46 -67 -40
Net Cash From Continuing Investing Activities		 -127 -2.00 -100 -142 -46 -67 -40
Purchase of Property, Plant & Equipment		 -0.15 -0.00 -0.30 -0.17 -37 -34 -0.31
Purchase of Investments		 - 0.00 0.00 -111 -127 -105 -86
Sale and/or Maturity of Investments		 - 0.00 0.00 9.07 118 99 81
Other Investing Activities, net		 -127 -2.00 -100 -40 0.00 -27 -34
Net Cash From Financing Activities		 144 209 7.42 6.84 -106 -11 -9.05
Net Cash From Continuing Financing Activities		 144 209 7.42 6.84 -106 -11 -9.05
Repayment of Debt		 -5.18 -126 -232 -2.00 -210 -15 -16
Repurchase of Common Equity		 0.00 -0.17 -0.30 0.00 -100 0.00 0.00
Issuance of Debt		 100 200 200 0.00 200 0.00 0.00
Other Financing Activities, net		 0.09 -12 9.37 8.84 4.54 4.00 7.20
Cash Interest Paid		 4.23 26 20 16 20 17 15
Cash Income Taxes Paid		 0.00 0.00 2.88 13 48 80 20

Quarterly Cash Flow Statements for Harmony Biosciences

This table details how cash moves in and out of Harmony Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 7.19 -13 21 -16 70 66 36 57 101 106 -163
Net Cash From Operating Activities		 63 77 31 43 71 76 34 79 109 126 28
Net Cash From Continuing Operating Activities		 63 77 31 43 71 76 34 64 124 125 28
Net Income / (Loss) Continuing Operations		 38 27 38 12 46 49 46 40 51 22 32
Consolidated Net Income / (Loss)		 38 27 38 12 46 49 46 40 51 22 32
Depreciation Expense		 0.14 0.16 0.16 0.09 0.01 0.01 0.01 0.01 0.01 - 0.01
Amortization Expense		 6.49 5.46 5.55 5.51 5.59 5.64 5.68 5.34 6.12 5.84 5.89
Non-Cash Adjustments To Reconcile Net Income		 18 12 11 54 12 11 13 12 41 15 43
Changes in Operating Assets and Liabilities, net		 -0.18 33 -24 -29 6.87 9.10 -30 7.02 26 81 -53
Net Cash From Investing Activities		 -0.81 -36 -6.19 -55 0.75 -7.19 2.36 -20 -4.79 -18 -184
Net Cash From Continuing Investing Activities		 -0.81 -36 -6.19 -55 0.75 -7.19 2.36 -4.59 -20 -18 -184
Purchase of Property, Plant & Equipment		 - -37 -0.01 -0.63 -0.00 -34 -0.13 -0.00 -0.07 -0.11 0.00
Purchase of Investments		 -33 -22 -25 -21 -23 -36 -19 -24 -24 -19 -179
Sale and/or Maturity of Investments		 32 23 19 26 24 30 22 19 20 21 27
Other Investing Activities, net		 - - - - - -1.00 0.00 - - -19 -32
Net Cash From Financing Activities		 -55 -54 -3.63 -3.45 -1.18 -2.74 -0.35 -2.69 -3.00 -3.02 -7.22
Net Cash From Continuing Financing Activities		 -55 -54 -3.63 -3.45 -1.18 -2.74 -0.35 -2.69 -3.00 -3.02 -7.22
Repayment of Debt		 -205 -3.75 -3.75 -3.75 -3.75 -3.75 -3.75 -3.75 -3.75 -5.00 -5.00
Other Financing Activities, net		 0.24 0.23 0.12 0.30 2.58 1.01 3.40 1.06 0.75 1.99 -2.22
Cash Interest Paid		 4.96 4.40 4.59 4.36 4.23 4.15 4.20 3.46 3.51 3.52 3.32

Annual Balance Sheets for Harmony Biosciences

This table presents Harmony Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 107 427 433 674 811 999 1,272
Total Current Assets		 31 263 284 400 451 579 907
Cash & Equivalents		 24 229 234 244 312 453 753
Short-Term Investments		 - - 0.00 79 42 14 23
Accounts Receivable		 4.26 22 35 55 74 83 97
Inventories, net		 1.09 3.82 4.43 4.30 5.36 7.20 5.36
Prepaid Expenses		 1.44 6.96 7.64 9.35 13 14 16
Other Current Assets		 0.26 1.30 3.22 8.79 5.54 8.12 14
Plant, Property, & Equipment, net		 1.33 0.94 0.82 0.57 0.37 0.00 0.00
Total Noncurrent Assets		 74 163 148 273 360 420 365
Long-Term Investments		 - - 0.00 23 72 109 107
Intangible Assets		 72 162 144 161 137 113 89
Noncurrent Deferred & Refundable Income Taxes		 - - 0.00 86 144 190 150
Other Noncurrent Operating Assets		 1.69 0.90 4.27 3.55 6.57 7.41 18
Total Liabilities & Shareholders' Equity		 107 427 433 674 811 999 1,272
Total Liabilities		 118 330 247 271 344 340 401
Total Current Liabilities		 20 135 54 79 164 175 252
Short-Term Debt		 - 0.00 2.00 2.00 15 16 20
Accounts Payable		 6.36 2.56 1.00 3.79 18 14 18
Accrued Expenses		 5.50 123 40 60 99 121 191
Current Employee Benefit Liabilities		 7.92 8.94 9.17 12 24 19 18
Other Current Liabilities		 0.12 0.31 1.36 1.62 7.81 5.67 4.96
Total Noncurrent Liabilities		 98 195 193 192 181 165 149
Long-Term Debt		 98 194 190 190 179 163 144
Other Noncurrent Operating Liabilities		 0.16 1.11 3.18 2.50 2.11 1.95 5.62
Total Equity & Noncontrolling Interests		 -423 97 187 403 467 659 870
Total Preferred & Common Equity		 -423 97 187 403 467 659 870
Total Common Equity		 -423 97 187 403 467 659 870
Common Stock		 0.00 585 640 675 610 657 709
Retained Earnings		 -423 -488 -454 -272 -143 2.22 161
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.15 0.00 0.07 0.35

Quarterly Balance Sheets for Harmony Biosciences

This table presents Harmony Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 643 715 760 778 847 858 928 1,056 1,108 1,208 1,272
Total Current Assets		 382 418 456 463 480 458 522 643 691 839 779
Cash & Equivalents		 261 288 317 325 333 317 387 489 546 647 589
Short-Term Investments		 46 56 54 46 39 30 23 18 19 26 52
Accounts Receivable		 55 53 64 67 80 83 82 106 93 101 108
Inventories, net		 3.90 4.09 4.85 5.09 5.86 5.64 6.92 6.38 6.10 6.88 5.28
Prepaid Expenses		 11 11 9.44 14 13 16 16 16 18 23 17
Other Current Assets		 4.11 6.15 6.55 5.70 8.68 6.51 7.46 6.92 8.64 35 7.60
Plant, Property, & Equipment, net		 0.68 0.47 0.57 0.43 0.21 0.75 0.75 1.38 1.38 1.44 0.00
Total Noncurrent Assets		 261 248 304 314 367 399 405 411 415 368 493
Long-Term Investments		 8.28 - 59 68 81 87 94 103 107 106 230
Intangible Assets		 167 155 149 143 131 125 119 107 101 95 83
Noncurrent Deferred & Refundable Income Taxes		 82 89 94 100 148 180 185 195 201 157 154
Other Noncurrent Operating Assets		 3.83 3.62 2.71 3.09 7.24 6.74 6.52 6.21 5.74 9.69 26
Total Liabilities & Shareholders' Equity		 643 715 760 778 847 858 928 1,056 1,108 1,208 1,272
Total Liabilities		 300 272 275 296 332 320 331 335 335 373 361
Total Current Liabilities		 107 85 93 112 154 147 161 175 180 223 217
Short-Term Debt		 2.00 6.50 11 15 15 15 15 18 19 20 20
Accounts Payable		 10 6.41 6.56 6.54 15 23 11 17 28 26 29
Accrued Expenses		 86 57 64 73 92 92 110 113 118 161 150
Current Employee Benefit Liabilities		 8.33 5.69 7.97 10 7.32 9.64 14 7.58 12 15 6.73
Other Current Liabilities		 1.37 9.95 3.95 7.79 25 7.61 12 20 3.06 0.83 12
Total Noncurrent Liabilities		 192 187 182 184 177 173 170 160 155 150 144
Long-Term Debt		 190 185 180 182 175 171 168 158 153 149 139
Other Noncurrent Operating Liabilities		 2.50 1.63 1.48 1.90 2.34 1.80 2.21 1.71 1.45 1.19 5.32
Total Equity & Noncontrolling Interests		 344 443 485 481 515 539 597 721 773 835 910
Total Preferred & Common Equity		 344 443 485 481 515 539 597 721 773 835 910
Total Common Equity		 344 443 485 481 515 539 597 721 773 835 910
Common Stock		 665 686 694 652 621 632 644 673 685 696 717
Retained Earnings		 -321 -243 -208 -170 -105 -93 -47 48 88 138 193
Accumulated Other Comprehensive Income / (Loss)		 -0.18 -0.03 -0.52 -0.52 -0.17 -0.23 0.50 0.25 0.24 0.36 -0.41

Annual Metrics And Ratios for Harmony Biosciences

This table displays calculated financial ratios and metrics derived from Harmony Biosciences' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 2,564.59% 91.21% 43.35% 32.93% 22.80% 21.51%
EBITDA Growth		 0.00% 118.69% 308.91% 33.46% 48.96% -1.22% 8.32%
EBIT Growth		 0.00% 109.54% 529.13% 37.48% 59.55% -0.66% 8.93%
NOPAT Growth		 0.00% 111.64% 580.46% 157.50% -31.50% 1.44% 6.27%
Net Income Growth		 0.00% 75.69% 193.65% 424.52% -28.99% 12.91% 9.07%
EPS Growth		 0.00% 89.70% 123.39% 412.07% -28.28% 17.84% 7.97%
Operating Cash Flow Growth		 0.00% 96.04% 3,401.74% 46.58% 51.86% 0.20% 58.40%
Free Cash Flow Firm Growth		 0.00% 0.00% -104.32% 21,912.47% 50.96% -25.07% 125.68%
Invested Capital Growth		 0.00% 1.45% 129.59% 72.56% -5.58% 11.68% -42.29%
Revenue Q/Q Growth		 0.00% 0.00% 12.91% 9.26% 7.40% 4.82% 5.15%
EBITDA Q/Q Growth		 0.00% 0.00% 22.99% 15.91% -3.52% 7.85% -6.96%
EBIT Q/Q Growth		 0.00% 0.00% 31.36% 18.77% -3.74% 8.84% -7.74%
NOPAT Q/Q Growth		 0.00% 0.00% 30.26% 12.48% -15.61% 18.07% -15.39%
Net Income Q/Q Growth		 0.00% 0.00% 196.28% 16.57% -14.53% 18.65% -14.54%
EPS Q/Q Growth		 0.00% 0.00% -89.45% 16.02% -13.41% 18.40% -14.78%
Operating Cash Flow Q/Q Growth		 0.00% 91.94% 38.67% -6.99% 29.51% -0.50% 17.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -13.60% 5.38% 33.73% 14.36%
Invested Capital Q/Q Growth		 0.00% 0.00% -6.61% 13.32% -2.15% -4.58% -32.77%
Profitability Metrics		 - - - - - - -
Gross Margin		 73.69% 82.64% 81.82% 80.93% 79.17% 78.06% 77.16%
EBITDA Margin		 -2,370.34% 16.63% 35.56% 33.11% 37.10% 29.84% 26.57%
Operating Margin		 -2,433.76% 10.63% 28.66% 27.45% 32.99% 26.70% 24.00%
EBIT Margin		 -2,433.76% 8.71% 28.66% 27.49% 32.99% 26.69% 23.93%
Profit (Net Income) Margin		 -2,535.06% -23.13% 11.33% 41.44% 22.14% 20.36% 18.27%
Tax Burden Percent		 100.00% 100.00% 92.44% 173.35% 74.31% 75.86% 73.79%
Interest Burden Percent		 104.16% -265.50% 42.75% 86.98% 90.30% 100.55% 103.50%
Effective Tax Rate		 0.00% 0.00% 7.56% -73.35% 25.69% 24.15% 26.21%
Return on Invested Capital (ROIC)		 -164.99% 19.07% 78.18% 106.03% 59.00% 58.22% 74.35%
ROIC Less NNEP Spread (ROIC-NNEP)		 -232.81% -230.66% 198.93% 133.39% 66.17% 57.98% 73.48%
Return on Net Nonoperating Assets (RNNOA)		 1,476.60% -105.39% -53.79% -44.45% -29.37% -32.38% -53.60%
Return on Equity (ROE)		 1,311.62% -86.32% 24.39% 61.58% 29.63% 25.84% 20.75%
Cash Return on Invested Capital (CROIC)		 0.00% 17.63% -0.46% 52.78% 64.74% 47.18% 127.98%
Operating Return on Assets (OROA)		 -136.74% 5.21% 20.35% 21.74% 25.86% 21.07% 18.30%
Return on Assets (ROA)		 -142.43% -13.84% 8.04% 32.78% 17.35% 16.07% 13.98%
Return on Common Equity (ROCE)		 47,866.81% 328.47% 24.39% 61.58% 29.63% 25.84% 20.75%
Return on Equity Simple (ROE_SIMPLE)		 35.94% -38.02% 18.55% 45.05% 27.59% 22.07% 0.00%
Net Operating Profit after Tax (NOPAT)		 -102 12 81 208 143 145 154
NOPAT Margin		 -1,703.63% 7.44% 26.49% 47.58% 24.52% 20.25% 17.71%
Net Nonoperating Expense Percent (NNEP)		 67.82% 249.73% -120.75% -27.37% -7.17% 0.24% 0.87%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 35.04% 21.60% 17.26% 14.88%
Cost of Revenue to Revenue		 26.31% 17.36% 18.18% 19.07% 20.83% 21.94% 22.84%
SG&A Expenses to Revenue		 607.32% 24.88% 20.92% 19.19% 16.37% 15.44% 17.56%
R&D to Revenue		 1,160.88% 12.17% 9.94% 16.19% 13.07% 20.40% 21.83%
Operating Expenses to Revenue		 2,507.46% 72.00% 53.17% 53.49% 46.18% 51.36% 53.16%
Earnings before Interest and Taxes (EBIT)		 -146 14 88 120 192 191 208
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -142 27 109 145 216 213 231
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 21.16 13.37 8.11 4.05 2.98 2.48
Price to Tangible Book Value (P/TBV)		 0.00 0.00 58.54 13.51 5.74 3.59 2.76
Price to Revenue (P/Rev)		 21.41 12.87 8.16 7.46 3.25 2.75 2.48
Price to Earnings (P/E)		 0.00 0.00 72.06 18.03 14.67 13.48 13.56
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 1.39% 5.55% 6.82% 7.42% 7.38%
Enterprise Value to Invested Capital (EV/IC)		 9.90 32.20 17.00 12.52 7.07 5.97 9.49
Enterprise Value to Revenue (EV/Rev)		 102.27 12.66 8.02 7.11 2.85 2.19 1.65
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 76.12 22.56 21.48 7.69 7.34 6.22
Enterprise Value to EBIT (EV/EBIT)		 0.00 145.32 28.00 25.88 8.64 8.21 6.91
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 170.07 30.29 14.95 11.63 10.82 9.34
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 24.87 21.56 7.57 7.12 4.13
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 183.91 0.00 30.03 10.60 13.35 5.43
Leverage & Solvency		 - - - - - - -
Debt to Equity		 -8.45 2.00 1.03 0.48 0.41 0.27 0.19
Long-Term Debt to Equity		 -8.45 2.00 1.02 0.47 0.38 0.25 0.17
Financial Leverage		 -6.34 0.46 -0.27 -0.33 -0.44 -0.56 -0.73
Leverage Ratio		 -9.21 6.24 3.03 1.88 1.71 1.61 1.48
Compound Leverage Factor		 -9.59 -16.56 1.30 1.63 1.54 1.62 1.54
Debt to Total Capital		 113.42% 66.65% 50.72% 32.24% 29.30% 21.38% 15.83%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.53% 0.34% 2.27% 1.94% 1.93%
Long-Term Debt to Total Capital		 113.42% 66.65% 50.20% 31.90% 27.03% 19.44% 13.90%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 476.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -489.66% 33.35% 49.28% 67.76% 70.70% 78.62% 84.17%
Debt to EBITDA		 -0.69 7.31 1.77 1.32 0.90 0.84 0.71
Net Debt to EBITDA		 -0.52 -1.29 -0.39 -1.06 -1.07 -1.86 -3.11
Long-Term Debt to EBITDA		 -0.69 7.31 1.75 1.31 0.83 0.76 0.62
Debt to NOPAT		 -0.96 16.34 2.37 0.92 1.36 1.24 1.06
Net Debt to NOPAT		 -0.72 -2.89 -0.52 -0.74 -1.63 -2.74 -4.67
Long-Term Debt to NOPAT		 -0.96 16.34 2.35 0.91 1.25 1.13 0.93
Altman Z-Score		 -9.22 2.98 6.60 8.48 4.97 5.30 5.24
Noncontrolling Interest Sharing Ratio		 -3,549.45% 480.50% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 1.58 1.95 5.29 5.07 2.75 3.31 3.60
Quick Ratio		 1.44 1.86 5.01 4.79 2.61 3.14 3.46
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 11 -0.48 104 157 117 265
Operating Cash Flow to CapEx		 -50,628.19% -149,250.00% 33,072.82% 83,991.86% 588.50% 642.34% 112,322.26%
Free Cash Flow to Firm to Interest Expense		 0.00 0.49 -0.01 5.52 4.67 6.71 18.07
Operating Cash Flow to Interest Expense		 0.00 -0.13 1.96 7.69 6.54 12.56 23.77
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -0.13 1.95 7.68 5.43 10.61 23.75
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.06 0.60 0.71 0.79 0.78 0.79 0.76
Accounts Receivable Turnover		 1.41 12.09 10.71 9.78 9.03 9.09 9.66
Inventory Turnover		 1.45 11.30 13.45 19.13 25.10 24.97 31.60
Fixed Asset Turnover		 4.51 140.87 347.49 628.65 1,233.10 878.05 0.00
Accounts Payable Turnover		 0.25 6.22 31.22 34.88 11.27 9.96 12.62
Days Sales Outstanding (DSO)		 259.06 30.20 34.07 37.34 40.41 40.13 37.79
Days Inventory Outstanding (DIO)		 251.82 32.31 27.14 19.08 14.54 14.62 11.55
Days Payable Outstanding (DPO)		 1,472.04 58.66 11.69 10.47 32.39 36.63 28.93
Cash Conversion Cycle (CCC)		 -961.15 3.85 49.51 45.96 22.56 18.12 20.41
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 62 63 144 249 235 262 151
Invested Capital Turnover		 0.10 2.56 2.95 2.23 2.41 2.87 4.20
Increase / (Decrease) in Invested Capital		 0.00 0.90 81 105 -14 27 -111
Enterprise Value (EV)		 613 2,022 2,451 3,114 1,660 1,566 1,436
Market Capitalization		 128 2,057 2,493 3,268 1,892 1,962 2,155
Book Value per Share		 ($54.37) $1.71 $3.19 $6.79 $7.97 $11.56 $15.11
Tangible Book Value per Share		 ($63.65) ($1.15) $0.73 $4.08 $5.63 $9.57 $13.56
Total Capital		 86 291 378 594 661 838 1,034
Total Debt		 98 194 192 192 194 179 164
Total Long-Term Debt		 98 194 190 190 179 163 144
Net Debt		 73 -34 -42 -154 -232 -397 -719
Capital Expenditures (CapEx)		 0.15 0.00 0.30 0.17 37 34 0.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -100 -1.65 0.29 -51 -47 -100
Debt-free Net Working Capital (DFNWC)		 12 128 233 323 302 420 675
Net Working Capital (NWC)		 12 128 231 321 287 404 655
Net Nonoperating Expense (NNE)		 50 49 46 27 14 -0.74 -4.87
Net Nonoperating Obligations (NNO)		 73 -34 -42 -154 -232 -397 -719
Total Depreciation and Amortization (D&A)		 3.80 13 21 25 24 23 23
Debt-free, Cash-free Net Working Capital to Revenue		 -214.38% -62.78% -0.54% 0.07% -8.79% -6.54% -11.57%
Debt-free Net Working Capital to Revenue		 193.58% 80.35% 76.17% 73.86% 51.94% 58.82% 77.71%
Net Working Capital to Revenue		 193.58% 80.35% 75.52% 73.40% 49.36% 56.55% 75.41%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.48) $0.60 $3.07 $2.17 $2.56 $2.76
Adjusted Weighted Average Basic Shares Outstanding		 0.00 25.77M 57.53M 59.17M 59.47M 56.89M 57.49M
Adjusted Diluted Earnings per Share		 $0.00 ($2.48) $0.58 $2.97 $2.13 $2.51 $2.71
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 25.77M 59.21M 61.10M 60.37M 57.87M 58.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 56.89M 58.87M 59.62M 56.77M 57.35M 57.84M
Normalized Net Operating Profit after Tax (NOPAT)		 -102 12 81 84 143 145 154
Normalized NOPAT Margin		 -1,703.63% 7.44% 26.49% 19.21% 24.52% 20.25% 17.71%
Pre Tax Income Margin		 -2,535.06% -23.13% 12.25% 23.91% 29.79% 26.84% 24.76%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.61 1.74 6.40 5.73 10.90 14.18
NOPAT to Interest Expense		 0.00 0.53 1.61 11.08 4.26 8.27 10.50
EBIT Less CapEx to Interest Expense		 0.00 0.61 1.73 6.39 4.62 8.95 14.16
NOPAT Less CapEx to Interest Expense		 0.00 0.53 1.60 11.08 3.14 6.32 10.48
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.45% 0.87% 0.00% 77.61% 0.00% 0.00%

Quarterly Metrics And Ratios for Harmony Biosciences

This table displays calculated financial ratios and metrics derived from Harmony Biosciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 57,840,614.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 57,840,614.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.55
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 36.74% 31.26% 29.79% 28.76% 16.08% 19.51% 19.48% 16.01% 28.71% 21.12% 16.59%
EBITDA Growth		 285.83% -14.74% 24.49% -48.76% -5.57% 34.29% 7.03% 97.57% 6.44% -28.02% -30.15%
EBIT Growth		 439.47% -15.71% 28.37% -54.36% -4.52% 39.04% 7.86% 124.31% 6.16% -31.20% -33.60%
NOPAT Growth		 -63.56% -48.54% 22.09% -68.72% -4.42% 82.20% 16.36% 238.36% 7.88% -56.68% -31.89%
Net Income Growth		 -56.27% -45.15% 30.01% -66.21% 19.84% 85.95% 18.85% 243.16% 10.35% -54.55% -28.69%
EPS Growth		 -56.25% -41.77% 39.58% -64.29% 25.40% 84.78% 16.42% 240.00% 10.13% -55.29% -29.49%
Operating Cash Flow Growth		 14.30% 187.37% -26.83% 14.99% 11.73% -1.44% 9.14% 86.14% 54.23% 66.95% -18.32%
Free Cash Flow Firm Growth		 -58.68% 178.12% 200.59% -4.38% -60.18% -46.92% -63.32% 274.35% 810.10% 510.26% 1,011.29%
Invested Capital Growth		 9.35% -5.58% 3.97% 17.77% 14.52% 11.68% 13.59% -6.20% -18.09% -42.29% -30.53%
Revenue Q/Q Growth		 19.41% 5.08% -8.19% 11.77% 7.65% 8.19% -8.22% 8.53% 19.44% 1.80% -11.65%
EBITDA Q/Q Growth		 35.03% -35.59% 25.18% -53.14% 148.86% -8.40% 0.19% -13.49% 34.06% -38.06% -2.77%
EBIT Q/Q Growth		 37.62% -37.68% 28.48% -58.77% 187.88% -9.25% 0.15% -14.26% 36.25% -41.19% -3.35%
NOPAT Q/Q Growth		 31.20% -43.71% 42.94% -70.38% 300.97% 7.31% -8.72% -13.85% 27.84% -56.90% 43.52%
Net Income Q/Q Growth		 12.13% -30.82% 44.07% -69.76% 297.66% 7.34% -7.91% -12.70% 27.88% -55.79% 44.48%
EPS Q/Q Growth		 12.50% -26.98% 45.65% -70.15% 295.00% 7.59% -8.24% -12.82% 27.94% -56.32% 44.74%
Operating Cash Flow Q/Q Growth		 70.25% 21.50% -59.38% 36.85% 65.43% 7.18% -55.02% 133.40% 37.07% 16.02% -77.99%
Free Cash Flow Firm Q/Q Growth		 187.87% 49.28% -29.18% -212.36% 133.52% 98.99% -51.06% 434.05% 74.97% 33.43% -10.87%
Invested Capital Q/Q Growth		 -2.81% -2.15% 7.18% 15.54% -5.49% -4.58% 9.01% -4.59% -17.47% -32.77% 31.22%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 79.85% 74.38% 82.22% 81.40% 77.01% 72.97% 82.68% 80.97% 75.09% 71.88% 79.33%
EBITDA Margin		 44.39% 27.21% 37.26% 15.62% 36.11% 30.57% 33.37% 26.60% 29.86% 18.17% 19.99%
Operating Margin		 40.25% 23.87% 33.65% 12.36% 33.17% 27.69% 30.45% 24.03% 27.35% 15.82% 17.31%
EBIT Margin		 40.25% 23.87% 33.56% 12.38% 33.10% 27.77% 30.30% 23.94% 27.30% 15.77% 17.25%
Profit (Net Income) Margin		 24.00% 15.80% 24.79% 6.71% 24.78% 24.58% 24.66% 19.84% 21.24% 9.22% 15.08%
Tax Burden Percent		 74.20% 67.04% 74.03% 53.43% 74.14% 88.10% 79.68% 80.13% 75.37% 55.17% 81.86%
Interest Burden Percent		 80.35% 98.74% 99.79% 101.41% 100.95% 100.48% 102.16% 103.44% 103.23% 106.00% 106.79%
Effective Tax Rate		 25.80% 32.96% 25.97% 46.57% 25.86% 11.90% 20.32% 19.87% 24.63% 44.83% 18.14%
Return on Invested Capital (ROIC)		 70.43% 38.50% 62.28% 16.11% 65.12% 70.12% 67.20% 52.77% 68.07% 36.63% 52.58%
ROIC Less NNEP Spread (ROIC-NNEP)		 75.57% 38.68% 62.36% 16.03% 65.00% 70.00% 66.99% 52.46% 67.75% 36.41% 52.24%
Return on Net Nonoperating Assets (RNNOA)		 -33.48% -17.17% -30.22% -7.61% -33.95% -39.09% -37.84% -29.91% -44.08% -26.56% -36.71%
Return on Equity (ROE)		 36.95% 21.33% 32.06% 8.50% 31.17% 31.03% 29.36% 22.86% 23.99% 10.07% 15.87%
Cash Return on Invested Capital (CROIC)		 64.65% 64.74% 56.69% 29.83% 34.07% 47.18% 43.45% 69.63% 92.58% 127.98% 93.66%
Operating Return on Assets (OROA)		 30.69% 18.71% 26.54% 10.04% 26.46% 21.92% 23.72% 18.81% 21.11% 12.06% 13.33%
Return on Assets (ROA)		 18.30% 12.38% 19.60% 5.44% 19.81% 19.41% 19.31% 15.59% 16.42% 7.06% 11.65%
Return on Common Equity (ROCE)		 36.95% 21.33% 32.06% 8.50% 31.17% 31.03% 29.36% 22.86% 23.99% 10.07% 15.87%
Return on Equity Simple (ROE_SIMPLE)		 31.32% 0.00% 26.72% 21.35% 20.55% 0.00% 21.20% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 48 27 39 11 46 49 45 39 49 21 31
NOPAT Margin		 29.87% 16.00% 24.91% 6.60% 24.59% 24.39% 24.26% 19.26% 20.61% 8.73% 14.17%
Net Nonoperating Expense Percent (NNEP)		 -5.15% -0.18% -0.08% 0.07% 0.12% 0.12% 0.21% 0.31% 0.32% 0.22% 0.34%
Return On Investment Capital (ROIC_SIMPLE)		 - 4.08% - - - 5.86% 5.00% 4.08% 4.92% 2.06% 2.86%
Cost of Revenue to Revenue		 20.15% 25.62% 17.78% 18.60% 22.99% 27.03% 17.32% 19.03% 24.91% 28.12% 20.67%
SG&A Expenses to Revenue		 14.07% 16.55% 16.61% 15.75% 15.37% 14.34% 16.91% 16.92% 12.45% 23.61% 15.09%
R&D to Revenue		 10.92% 18.00% 14.35% 36.79% 13.65% 17.22% 18.70% 25.02% 22.95% 20.48% 32.21%
Operating Expenses to Revenue		 39.60% 50.51% 48.57% 69.04% 43.84% 45.28% 52.23% 56.94% 47.74% 56.07% 62.02%
Earnings before Interest and Taxes (EBIT)		 65 40 52 21 62 56 56 48 65 38 37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 71 46 58 27 67 62 62 53 72 44 43
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.08 4.05 0.00 3.18 3.81 2.98 2.64 2.35 1.90 2.48 1.78
Price to Tangible Book Value (P/TBV)		 5.81 5.74 0.00 4.14 4.76 3.59 3.10 2.70 2.14 2.76 1.96
Price to Revenue (P/Rev)		 3.63 3.25 0.00 2.61 3.33 2.75 2.56 2.35 1.92 2.48 1.80
Price to Earnings (P/E)		 13.07 14.67 0.00 14.86 18.39 13.48 12.43 10.00 8.55 13.56 11.18
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 7.65% 6.82% 0.00% 6.73% 5.44% 7.42% 8.05% 10.00% 11.70% 7.38% 8.95%
Enterprise Value to Invested Capital (EV/IC)		 7.18 7.07 0.00 5.04 7.10 5.97 5.14 4.82 4.33 9.49 4.57
Enterprise Value to Revenue (EV/Rev)		 3.18 2.85 0.00 2.23 2.86 2.19 1.97 1.70 1.18 1.65 1.01
Enterprise Value to EBITDA (EV/EBITDA)		 7.71 7.69 0.00 7.27 9.87 7.34 6.76 5.39 3.93 6.22 4.28
Enterprise Value to EBIT (EV/EBIT)		 8.65 8.64 0.00 8.23 11.14 8.21 7.54 5.94 4.33 6.91 4.81
Enterprise Value to NOPAT (EV/NOPAT)		 10.20 11.63 0.00 11.81 15.92 10.82 9.72 7.37 5.37 9.34 6.50
Enterprise Value to Operating Cash Flow (EV/OCF)		 10.18 7.57 0.00 6.86 8.83 7.12 6.60 5.07 3.28 4.13 2.66
Enterprise Value to Free Cash Flow (EV/FCFF)		 11.61 10.60 0.00 18.27 22.24 13.35 12.57 6.70 4.21 5.43 4.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.41 0.41 0.37 0.35 0.31 0.27 0.24 0.22 0.20 0.19 0.17
Long-Term Debt to Equity		 0.38 0.38 0.34 0.32 0.28 0.25 0.22 0.20 0.18 0.17 0.15
Financial Leverage		 -0.44 -0.44 -0.48 -0.47 -0.52 -0.56 -0.56 -0.57 -0.65 -0.73 -0.70
Leverage Ratio		 1.72 1.71 1.63 1.58 1.58 1.61 1.54 1.50 1.49 1.48 1.43
Compound Leverage Factor		 1.38 1.69 1.63 1.60 1.60 1.62 1.57 1.55 1.54 1.57 1.52
Debt to Total Capital		 29.06% 29.30% 26.93% 25.71% 23.45% 21.38% 19.60% 18.21% 16.79% 15.83% 14.85%
Short-Term Debt to Total Capital		 2.21% 2.27% 2.13% 2.07% 1.92% 1.94% 1.95% 1.98% 1.99% 1.93% 1.87%
Long-Term Debt to Total Capital		 26.84% 27.03% 24.81% 23.64% 21.53% 19.44% 17.65% 16.22% 14.80% 13.90% 12.98%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 70.94% 70.70% 73.07% 74.29% 76.55% 78.62% 80.40% 81.79% 83.21% 84.17% 85.15%
Debt to EBITDA		 0.88 0.90 0.84 0.92 0.92 0.84 0.81 0.71 0.68 0.71 0.75
Net Debt to EBITDA		 -1.08 -1.07 -1.16 -1.23 -1.63 -1.86 -2.00 -2.05 -2.46 -3.11 -3.35
Long-Term Debt to EBITDA		 0.81 0.83 0.77 0.85 0.85 0.76 0.73 0.63 0.60 0.62 0.65
Debt to NOPAT		 1.17 1.36 1.27 1.50 1.49 1.24 1.16 0.97 0.93 1.06 1.14
Net Debt to NOPAT		 -1.43 -1.63 -1.76 -2.00 -2.63 -2.74 -2.88 -2.81 -3.36 -4.67 -5.10
Long-Term Debt to NOPAT		 1.08 1.25 1.17 1.38 1.37 1.13 1.05 0.86 0.82 0.93 0.99
Altman Z-Score		 5.19 4.35 0.00 4.34 5.47 4.85 4.88 4.76 4.18 4.80 4.24
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.12 2.75 3.11 3.13 3.24 3.31 3.67 3.84 3.75 3.60 3.58
Quick Ratio		 3.90 2.61 2.93 2.93 3.05 3.14 3.50 3.65 3.46 3.46 3.45
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 27 41 29 -32 11 22 11 57 99 132 118
Operating Cash Flow to CapEx		 0.00% 206.79% 622,820.00% 6,743.20% 2,350,033.33% 225.01% 26,552.34% 1,983,175.00% 153,146.48% 117,898.13% 0.00%
Free Cash Flow to Firm to Interest Expense		 1.63 8.51 6.37 -7.38 2.50 5.15 2.76 15.53 27.37 37.29 36.44
Operating Cash Flow to Interest Expense		 3.76 15.99 6.87 9.68 16.21 17.95 8.86 21.76 30.03 35.58 8.58
Operating Cash Flow Less CapEx to Interest Expense		 3.76 8.26 6.87 9.53 16.21 9.97 8.83 21.76 30.01 35.55 8.58
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.76 0.78 0.79 0.81 0.80 0.79 0.78 0.79 0.77 0.76 0.77
Accounts Receivable Turnover		 8.86 9.03 9.34 8.93 9.17 9.09 8.02 8.77 9.07 9.66 8.40
Inventory Turnover		 23.36 25.10 25.72 25.74 24.26 24.97 26.36 28.50 26.70 31.60 36.15
Fixed Asset Turnover		 978.19 1,233.10 1,808.23 989.61 1,157.69 878.05 936.33 725.38 754.29 0.00 0.00
Accounts Payable Turnover		 12.66 11.27 11.87 9.24 17.05 9.96 9.90 6.56 9.99 12.62 9.16
Days Sales Outstanding (DSO)		 41.20 40.41 39.10 40.88 39.82 40.13 45.50 41.61 40.25 37.79 43.48
Days Inventory Outstanding (DIO)		 15.62 14.54 14.19 14.18 15.05 14.62 13.85 12.81 13.67 11.55 10.10
Days Payable Outstanding (DPO)		 28.84 32.39 30.75 39.51 21.40 36.63 36.88 55.60 36.53 28.93 39.86
Cash Conversion Cycle (CCC)		 27.98 22.56 22.54 15.55 33.46 18.12 22.46 -1.19 17.39 20.41 13.71
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 240 235 252 291 275 262 286 273 225 151 199
Invested Capital Turnover		 2.36 2.41 2.50 2.44 2.65 2.87 2.77 2.74 3.30 4.20 3.71
Increase / (Decrease) in Invested Capital		 21 -14 9.61 44 35 27 34 -18 -50 -111 -87
Enterprise Value (EV)		 1,725 1,660 0.00 1,466 1,952 1,566 1,469 1,314 976 1,436 908
Market Capitalization		 1,966 1,892 0.00 1,713 2,273 1,962 1,903 1,815 1,586 2,155 1,620
Book Value per Share		 $8.02 $7.97 $9.08 $9.48 $10.50 $11.56 $12.56 $13.46 $14.52 $15.11 $15.74
Tangible Book Value per Share		 $5.64 $5.63 $6.77 $7.28 $8.40 $9.57 $10.69 $11.70 $12.86 $13.56 $14.30
Total Capital		 678 661 705 725 780 838 896 945 1,004 1,034 1,069
Total Debt		 197 194 190 186 183 179 176 172 169 164 159
Total Long-Term Debt		 182 179 175 171 168 163 158 153 149 144 139
Net Debt		 -241 -232 -264 -248 -322 -397 -435 -500 -610 -719 -712
Capital Expenditures (CapEx)		 0.00 37 0.01 0.63 0.00 34 0.13 0.00 0.07 0.11 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.08 -51 -32 -20 -34 -47 -22 -35 -37 -100 -59
Debt-free Net Working Capital (DFNWC)		 366 302 340 327 376 420 485 530 635 675 581
Net Working Capital (NWC)		 351 287 325 312 361 404 468 511 615 655 561
Net Nonoperating Expense (NNE)		 9.41 0.34 0.18 -0.18 -0.34 -0.38 -0.74 -1.17 -1.51 -1.22 -1.96
Net Nonoperating Obligations (NNO)		 -241 -232 -264 -248 -322 -397 -435 -500 -610 -719 -712
Total Depreciation and Amortization (D&A)		 6.64 5.63 5.71 5.60 5.59 5.65 5.68 5.35 6.12 5.84 5.90
Debt-free, Cash-free Net Working Capital to Revenue		 -0.94% -8.79% -5.20% -3.07% -5.04% -6.54% -2.94% -4.57% -4.50% -11.57% -6.61%
Debt-free Net Working Capital to Revenue		 67.46% 51.94% 55.10% 49.80% 55.16% 58.82% 65.12% 68.60% 76.93% 77.71% 64.67%
Net Working Capital to Revenue		 64.69% 49.36% 52.67% 47.52% 52.96% 56.55% 62.77% 66.17% 74.51% 75.41% 62.45%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.64 $0.47 $0.68 $0.20 $0.81 $0.87 $0.79 $0.69 $0.88 $0.40 $0.56
Adjusted Weighted Average Basic Shares Outstanding		 59.86M 59.47M 56.77M 56.80M 56.87M 56.89M 57.31M 57.47M 57.55M 57.49M 57.82M
Adjusted Diluted Earnings per Share		 $0.63 $0.46 $0.67 $0.20 $0.79 $0.85 $0.78 $0.68 $0.87 $0.38 $0.55
Adjusted Weighted Average Diluted Shares Outstanding		 60.68M 60.37M 57.60M 57.54M 58.10M 57.87M 58.52M 58.43M 58.72M 58.54M 58.78M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 58.57M 56.77M 56.79M 56.83M 57.03M 57.35M 57.42M 57.53M 57.60M 57.84M 57.89M
Normalized Net Operating Profit after Tax (NOPAT)		 48 27 39 11 46 49 45 39 49 21 31
Normalized NOPAT Margin		 29.87% 16.00% 24.91% 6.60% 24.59% 24.39% 24.26% 19.26% 20.61% 8.73% 14.17%
Pre Tax Income Margin		 32.34% 23.57% 33.49% 12.55% 33.42% 27.90% 30.95% 24.76% 28.18% 16.72% 18.43%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 3.84 8.38 11.44 4.86 14.16 13.28 14.59 13.16 18.06 10.84 11.49
NOPAT to Interest Expense		 2.85 5.62 8.49 2.59 10.52 11.67 11.68 10.59 13.63 6.00 9.44
EBIT Less CapEx to Interest Expense		 3.84 0.65 11.44 4.71 14.16 5.30 14.56 13.16 18.04 10.81 11.49
NOPAT Less CapEx to Interest Expense		 2.85 -2.11 8.49 2.45 10.52 3.69 11.65 10.59 13.61 5.97 9.44
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 33.17% 77.61% 0.00% 0.00% 40.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are key trends from Harmony Biosciences (HRMY) based on the quarterly statements provided for 2025 (through Q4) and referenced prior periods. The focus is on trends over the last four years, with an emphasis on what may matter to retail investors.

  • Revenue growth in 2025: Total operating revenue rose from about $184.7M in Q1 2025 to $243.8M in Q4 2025, signaling solid top-line momentum by year-end.
  • Strong gross margins across 2025: Gross margin remained robust, generally in the mid-70s to low-80s percent range (Q4 2025 roughly 72%), indicating pricing power and relatively disciplined cost of goods sold.
  • Significant cash flow from operations in 2025: Net cash from continuing operating activities was strong through 2025, with Q4 2025 at about $124.7M and steady increases vs earlier quarters.
  • Healthy liquidity buildup in 2025: Cash and cash equivalents climbed across 2025, peaking around $646–$648M in mid-to-late 2025, providing a substantial liquidity cushion.
  • Solid near-term liquidity metrics: The company maintained a healthy current ratio (roughly 3.8x in Q3 2025, given Total Current Assets around $839M and Total Current Liabilities around $223M), suggesting good ability to cover near-term obligations.
  • Strong balance sheet framework: As of mid-2025, Total Equity was about $835M with Total Assets around $1.21B, indicating a solid equity base relative to liabilities.
  • Restatements noted in prior quarters: Some prior periods (e.g., Q4 2024 and Q3 2024) show restated or restated-like disclosures, which may affect year-over-year comparability but do not reflect current-year operational performance alone.
  • Q4 2025 net income declined vs. the prior quarter: Net income attributable to common shareholders dropped to about $22.5M in Q4 2025 from approximately $51.0M in Q3 2025, signaling quarterly earnings volatility.
  • Margin pressure from higher operating expenses in Q4 2025: Total operating expenses rose to about $136.7M in Q4 2025 from $114.3M in Q3 2025, which pressurized quarterly profitability.
  • Earnings per share showed volatility across 2025: Diluted EPS dropped in Q4 2025 to about $0.38 (vs. $0.87 in Q3 2025), reflecting quarterly mix and cost dynamics that could concern investors focused on consistency.
05/15/26 02:58 PM ETAI Generated. May Contain Errors.

Harmony Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Harmony Biosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Harmony Biosciences' net income appears to be on an upward trend, with a most recent value of $158.69 million in 2025, falling from -$151.98 million in 2019. The previous period was $145.49 million in 2024. View Harmony Biosciences' forecast to see where analysts expect Harmony Biosciences to go next.

Harmony Biosciences' total operating income in 2025 was $208.47 million, based on the following breakdown:
  • Total Gross Profit: $670.11 million
  • Total Operating Expenses: $461.64 million

Over the last 6 years, Harmony Biosciences' total revenue changed from $6.00 million in 2019 to $868.45 million in 2025, a change of 14,386.3%.

Harmony Biosciences' total liabilities were at $401.41 million at the end of 2025, a 18.0% increase from 2024, and a 239.4% increase since 2019.

In the past 6 years, Harmony Biosciences' cash and equivalents has ranged from $24.46 million in 2019 to $752.50 million in 2025, and is currently $752.50 million as of their latest financial filing in 2025.

Over the last 6 years, Harmony Biosciences' book value per share changed from -54.37 in 2019 to 15.11 in 2025, a change of -127.8%.


Related Companies

Financial statements for NASDAQ:HRMY last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel